Protalix BioTherapeutics Announces FDA Acceptance Of BLA For The Treatment Of Fabry Disease And Grants Priority Review

Investor Contact:
Chuck Padala, Managing Director
LifeSci Advisors
+1-646-627-8390
chuck@lifesciadvisors.com

Media Contact:
Brian Pinkston
LaVoieHealthScience
+1-857-588-3347
bpinkston@lavoiehealthscience.com

Chiesi Global Rare Diseases (PRNewsfoto/Protalix BioTherapeutics, Inc.)

SOURCE: Protalix BioTherapeutics, Inc.

Related Article: Protalix BioTherapeutics Pipeline Progress

1 2 3 4
View single page >> |
How did you like this article? Let us know so we can better customize your reading experience.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.